ERBB2 and non-small cell lung carcinoma: Recently, Saalfeld et al. reported on the efficacy of immunotherapy (either alone or combined with chemotherapy) in patients with HER2-mutant NSCLC comparing patients in the first versus subsequent lines of therapy [98].